PBC in the News

Summary News

Back

• Rising awareness and media coverage of liver diseases, particularly PBC, including expert discussions and patient stories on various platforms.
• Promising clinical trial results for new PBC treatments such as linerixibat, seladelpar (Livdelzi), and elafibranor (Iqirvo), showing improvements in symptoms like itch and fatigue.
• Regulatory progress with multiple approvals and conditional authorizations of PBC treatments across Europe, the US, and the UK (e.g., Livdelzi, Iqirvo).
• Ongoing research into the mechanisms and associated conditions of PBC, including links to lymphoma, systemic sclerosis, and gut microbiota.
• Growing investment and milestone payments in the PBC drug development sector, reflecting commercial interest and expanding treatment options.
• Studies highlighting the importance of early diagnosis, personalized treatment plans, and quality of life improvements for PBC patients.
• Concerns over safety and effectiveness of existing treatments, with regulatory bodies declining or revoking approvals (e.g., Ocaliva).
• Educational efforts through art, patient stories, and physician guidance to support awareness and understanding of rare liver diseases like PBC.

News Articles

Back

01/04/2026 Ipsen’s Luminaria Study: Fresh Digital Symptom Data in Primary Biliary Cholangitis - TipRanks

31/03/2026 The impact of male sex on outcomes in primary biliary cholangitis - Nature

25/03/2026 Study indicates which PBC patients may see liver function recovery - Liver Disease News

23/03/2026 FDA Approves Lynavoy for PBC-Associated Pruritus - Gastroenterology & Endoscopy News

22/03/2026 FDA Approves First Drug for Cholestatic Pruritus in Primary Biliary Cholangitis - Medical Dialogues

20/03/2026 Protect Your Well-Being With Primary Biliary Cholangitis - Everyday Health

19/03/2026 FDA OKs linerixibat, now Lynavoy, as first US treatment for itch in PBC - Liver Disease News

19/03/2026 FDA approves first drug for itch due to primary biliary cholangitis - FirstWord Pharma

19/03/2026 FDA Approves Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis - AJMC

19/03/2026 FDA Approves Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis - Pharmacy Times

19/03/2026 FDA OKs First Drug for Liver Disease-Related Pruritus - medpagetoday.com

09/03/2026 Breaking the metabolo-immune cycle in primary biliary cholangitis for therapeutic benefit - Frontiers

03/03/2026 COUR Pharma Announces Positive One-Year Results from the - GlobeNewswire

12/02/2026 Osteoporosis in primary biliary cholangitis: from cholestasis to fracture prevention - Termedia

11/02/2026 Primary biliary cholangitis–associated osteoporosis: contemporary review of pathogenesis and management - EurekAlert!

11/02/2026 Noninvasive combo tests for liver damage could replace biopsies in PBC - Liver Disease News

02/02/2026 Assessing Disease Severity and Progression Risk in PBC - HCPLive

28/01/2026 Could the sun lower PBC risk? Study explores benefits of UV exposure. - Liver Disease News

22/01/2026 Closing Gaps in PBC Care With Emerging and Established Second-Line Treatments - HCPLive

14/01/2026 Diagnostic potential of salivary biomarkers for primary biliary cholangitis: a systematic review - Frontiers

02/01/2026 Seladelpar reduced pruritus in PBC as early as ‘first month, and persisted’ - Healio

23/12/2025 Vitamin D3 attenuates hepatic inflammation in primary biliary cholangitis by inhibiting TLR4/NF-κB mediated M1 macrophage polarization | Scientific Reports - Nature

22/12/2025 Treating primary biliary cholangitis - mcpress.mayoclinic.org

17/12/2025 RIPK1 inhibition reduces biliary injury and fibrosis in primary sclerosing cholangitis - Science | AAAS

17/12/2025 Compound found in honey reduced inflammation in PBC mice in lab - Liver Disease News

10/12/2025 Major Developments in the PBC Pruritus Treatment Pipeline - Gastroenterology & Endoscopy News

03/12/2025 Shifts in Blood Lipids Linked to Early Primary Biliary Cholangitis - EMJ

03/12/2025 Linerixibat offers PBC patients fast relief from intense itching in trial - Liver Disease News

02/12/2025 Strength and Spirit: Anna’s Experience with a Rare Liver Disease - Reader's Digest

27/11/2025 Altered sphingolipid profile in primary biliary cholangitis: associations with fibrosis and inflammation - Nature

27/11/2025 Pruritus Exhausts Patients With Primary Sclerosing Cholangitis - Medscape

26/11/2025 Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome with primary biliary cholangitis and alcoholic liver disease: a case report - Frontiers

25/11/2025 Meet Wendy, living with PBC - Ipsen

21/11/2025 Patients with Primary Biliary Cholangitis Miss Recommended Monitoring - EMJ

20/11/2025 VIDEO: Iqirvo may stabilize primary biliary cholangitis progression after long-term use - Healio

19/11/2025 Living with PBC: The Person Behind the Chart - Ipsen

19/11/2025 Blood group A linked to a higher risk of primary biliary cholangitis - News-Medical

18/11/2025 Primary Biliary Cholangitis (PBC) Treatment Market to Reach USD 2.72 Billion by 2033, Driven by Next-Generation FXR Agonists & Immunomodulators | DataM Intelligence - PR Newswire

13/11/2025 VIDEO: Livdelzi appears safe for patients with PBC, advanced liver disease - Healio

12/11/2025 GLISTEN: Linerixibat Improves Biomarkers and Itch in Patients With PBC, With Andreas Kremer, MD, PhD, MHBA - HCPLive

12/11/2025 Livdelzi maintains benefits for up to 3 years in PBC: Phase 3 data - Liver Disease News

12/11/2025 VIDEO: Livdelzi demonstrates benefit in PBC regardless of prior fibrate, OCA use - Healio

11/11/2025 Long-Term Elafibranor Treatment Leads to Biochemical, Symptomatic Improvements in PBC - HCPLive

10/11/2025 Seladelpar Staves Off Liver Stiffness in PBC - Medscape

09/11/2025 Elafibranor Benefits Fatigue-Related Pathways Linked to Mitochondrial Function in PBC - HCPLive

08/11/2025 Seladelpar’s Long-Term Benefit for Pruritus in PBC, With Gideon Hirschfield, FRCP, PhD - HCPLive

07/11/2025 Volixibat Improves Fatigue and Sleep in Patients With Primary Biliary Cholangitis - HCPLive

07/11/2025 Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue - Yahoo Finance

06/11/2025 Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression - Business Wire

05/11/2025 Most recent liver stiffness test best predicts risk of PBC progression - Liver Disease News

05/11/2025 Gilead’s Research Scholars Program Supports New Investigations into Rare Liver Disease - Gilead Sciences

31/10/2025 Integrative multi-omics and causal inference unveil novel therapeutic targets for primary sclerosing cholangitis and its genetic comorbidity with inflammatory bowel disease - Nature

30/10/2025 Ipsen at The Liver Meeting 2025 - Ipsen

30/10/2025 Elafibranor More Cost-Effective Than Seladelpar for Second-Line PBC Treatment - HCPLive

27/10/2025 Exploring primary biliary cholangitis - Healio

24/10/2025 Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - BioSpace

15/10/2025 Women with PBC may be at high risk of disease flares after childbirth - Liver Disease News

14/10/2025 Primary biliary cholangitis. Treatment options in 2025. A narrative review - Frontiers

14/10/2025 Multi-omics tests identify novel shared genetic mechanisms of primary biliary cholestasis and sarcopenia - Nature

10/10/2025 Bezafibrate for primary biliary cholangitis: time to act on the evidence - Nature

09/10/2025 Beyond Ursodeoxycholic Acid: A Comprehensive Review of Second-Line Agents in Primary Biliary Cholangitis - Cureus

08/10/2025 The role of mitochondria-related key genes in primary biliary cholangitis was analyzed based on transcriptome sequencing data - Frontiers

07/10/2025 Linerixibat Reduces Itching in PBC - Medscape

03/10/2025 Non-Response to Obeticholic Acid May Predict Clinical Outcomes in Primary Biliary Cholangitis - Medscape

01/10/2025 PBC worst for life quality among autoimmune liver diseases: Study - Liver Disease News

19/09/2025 Mixed Multiple Autoimmune Syndrome Type 3 With Coexistence of Primary Biliary Cholangitis, Inflammatory Myopathy, and Chronic Thyroiditis: A Case Report - Cureus

17/09/2025 PBC treatment Ocaliva leaves U.S. market amid safety concerns - Liver Disease News

15/09/2025 Common pathological mechanisms and therapeutic strategies in primary Sjogren’s syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy - Frontiers

12/09/2025 Liver Disease Drug Pulled From the Market - medpagetoday.com

11/09/2025 Ocaliva for PBC Withdrawn From US Market - Medscape

11/09/2025 Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold - Yahoo Finance

11/09/2025 Intercept Voluntarily Withdraws Obeticholic Acid (Ocaliva) for PBC From US Market - HCPLive

10/09/2025 Gilead fashions new primary biliary cholangitis campaign alongside 'Project Runway' designer - Fierce Pharma

10/09/2025 September's PBC Awareness Month raises support for a rare liver... - Liver Disease News

08/09/2025 Progress in PBC, PSC: Key Updates in Cholestatic Liver Disease Care With Ann Moore, NP - HCPLive

05/09/2025 Innate immunity of bile and cholangiocytes in primary biliary cholangitis - Frontiers

01/09/2025 Beyond tired: Understanding fatigue in Primary Biliary Cholangitis - Ipsen

29/08/2025 Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis - PR Newswire

29/08/2025 Zydus' phase 3 liver disease win tees up filing to challenge Gilead and Ipsen - Fierce Biotech

28/08/2025 Genetic architecture of primary biliary cholangitis: strong evidence for HLA and non-HLA risk loci - Frontiers

27/08/2025 Local Woman Launches Support Group For People With Primary Biliary Cholangitis - The Citizen Newspaper Group

26/08/2025 An experimental study on the effect of symptom expectations on mental fatigue and motivation in people with primary biliary cholangitis - Nature

25/08/2025 Understanding PBC: Managing what Matters Most - Ipsen

19/08/2025 FDA Approves Wegovy for a Severe Liver Disease Known as MASH - HealthCentral

07/08/2025 Dendritic Cell-Depleted Mice Develop the Autoimmune Biliary Disease That Serologically and Pathogenically Models Human Primary Biliary Cholangitis - Wiley Online Library

03/08/2025 Research progress and perspectives of non-coding RNAs in primary biliary cholangitis: from mechanisms to therapeutics - Frontiers

23/07/2025 PPAR agonists effective in UDCA-resistant primary biliary cholangitis - Liver Disease News

02/07/2025 Endothelial cells expressing CPE and vWF are involved in the Immunopathogenesis of primary biliary cholangitis - Nature

30/06/2025 Treatment of pruritus in primary biliary cholangitis - Clínica FEHV

27/06/2025 Gilead Art Campaign Captures The PBC Patient Experience, Inspires Patient-Centric Trials - Clinical Leader

25/06/2025 EMA to review linerixibat for primary biliary cholangitis-related itch - Liver Disease News

20/06/2025 Novel Therapies for Adults With Primary Biliary Cholangitis - Medscape Reference

12/06/2025 Primary biliary cholangitis and the narrowing gap towards optimal disease control - The Lancet

22/05/2025 New Kids on the Block: Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis - EMJ

19/05/2025 Double Trouble: Drug-Induced Autoimmune Hepatitis (AIH)-Primary Biliary Cholangitis (PBC) Overlap Syndrome Triggered by Hydralazine - Cureus

15/05/2025 Betrayed by bile ducts? Researchers look for clues to treating a mysterious autoimmune disease - Medical Xpress

09/05/2025 Gilead’s Livdelzi Shows Lasting Efficacy in Primary Biliary Cholangitis, Regardless of Prior Therapy - Pharmaceutical Executive

08/05/2025 Iqirvo Shows Significant Fatigue Improvement in Patients with Primary Biliary Cholangitis After 52 Weeks in Phase III ELATIVE Trial - Applied Clinical Trials

07/05/2025 Bringing PBC Into Focus Through Art of Patient Stories - Gilead Sciences

10/04/2025 Systemic Sclerosis and Primary Biliary Cholangitis: A Comprehensive Review of Two Overlapping Rare Entities With Insights on Diagnostics and Management - Cureus